Skip to content

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080224855
Enrollment
18
Registered
2019-09-04
Start date
2019-10-21
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : caplacizumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investi

Sponsors

None listed

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
efficacy

Secondary

MeasureTime frame
efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy efficacy safety pharmacodynamics pharmacokinetics other

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026